Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in DLBCL With Specific Mutations or CD5+
NCT06846463Phase 2Recruiting
- Sponsor
- Virginia Commonwealth University
- Start
- May 2025
- Primary completion
- Jul 2029
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Virginia Commonwealth University. Primary endpoint: Complete Response at 2 years. Started May 2025; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06846463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846463.